Effects of a 7-day continuous infusion of octreotide on circulating levels of growth factors and binding proteins in growth hormone (GH)-treated GH-deficient patients

Growth Hormone and IGF Research

Volumn 9, Issue 6, 1999, Pages 451-457

  Laursen, Torben ^a   Møller, Jens ^b   Fisker, Sanne ^b   Jørgensen, Jens O L ^b   Christiansen, Jens S ^b  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Growth hormone; Growth hormone deficiency; Insulin like growth factor; Octreotide

Indexed keywords

GLUCOSE; GROWTH HORMONE; INSULIN; OCTREOTIDE; PROTEIN SUBUNIT; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; HORMONE BLOOD LEVEL; HORMONE RELEASE; HORMONE SUBSTITUTION; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME;

EID: 0033388419     PISSN: 10966374     EISSN: None     Source Type: Journal    
DOI: 10.1054/ghir.1999.0131     Document Type: Article

References (44)

1. Williams G., Fuessl H., Kraenzlin M., Bloom S. R. Postprandial effects of SMS 201-995 on gut hormones and glucose tolerance. Scand J Gastroenterol. 119(Suppl. 83):1986;73-83.
2. Ørskov H., Flyvbjerg A., Frystyk J., Ledet T., Møller N., Christensen S. E., Harris A. G. Octreotide and diabetes: theoretical and experimental aspects. Metabolism. 41:1992;66-71.
3. Oppizzi G., Petroncini M. M., Dallabonzana D., Cozzi R., Verde G., Chiodini P. G., Liuzzi A. Relationship between somatomedin-C and growth hormone levels in acromegaly: basal and dynamic evaluation. J Clin Endocrinol Metab. 63:1986;1348-1353.
4. Barkan A. L., Beitins I. Z., Kelch R. P. Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. J Clin Endocrinol Metab. 67:1988;69-73.
5. Stonesifer L. D., Jordan R. M., Kohler P. O. Somatomedin C in treated acromegaly: poor correlation with growth hormone and clinical response. J Clin Endocrinol Metab. 53:1981;931-934.
6. Quabbe H. J., Plockinger U. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly. J Clin Endocrinol Metab. 68:1989;873-881.
7. Tauber J. P., Babin T., Tauber M. T., Vigoni F., Bonafe A., Ducasse M., Harris A. G., Bayard F. Long term effects of continuous subcutaneous infusion of the somatostatin analog octreotide in the treatment of acromegaly. J Clin Endocrinol Metab. 68:1989;917-924.
8. Vance M. L., Harris A. G. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group. Arch Intern Med. 151:1991;1573-1578.
9. Miyazaki R., Yoshida T., Sakane N., Yasuda T., Umekawa T., Kondo M., Shimatsu A., Hizuka N., Sano T. Acromegalic gigantism with low serum level of growth hormone and elevated serum insulin-like growth factor-I. Intern Med. 34:1995;183-187.
10. Hyer S. L., Sharp P. S., Broks R. A., Burrin J. M., Kohner E. M. Continuous subcutaneous octreotide infusion markedly suppresses IGF-I levels whilst only partially suppressing GH secretion in diabetics with retinopathy. Acta Endocrinol Copenh. 120:1989;187-194.
11. Flyvbjerg A., Jørgensen K. D., Marshall S. M., Ørskov H. Inhibitory effect of octreotide on growth hormone-induced IGF-I generation and organ growth in hypophysectomized rats. Am J Physiol. 260:1991;E568-E574.
12. Serri O., Brazeau P., Kachra Z., Posner B. Octreotide inhibits insulin-like growth factor-I hepatic gene expression in the hypophysectomized rat: evidence for a direct and indirect mechanism of action. Endocrinology. 130:1992;1816-1821.
13. Ross M., Francis G. L., Szabo L., Wallace J. C., Ballard F. J. Insulin-like growth factor (IGF) binding proteins inhibits the biological activities of IGF-I, IGF-II but not des-(1-3)-IGF-I. Biochem J. 258:1989;267-272.
14. Snyder D. K., Clemmons D. R. Insulin-dependent regulation of insulin-like growth factor-binding protein-1. J Clin Endocrinol Metab. 71:1990;1632-1636.
15. Ezzat S., Ren S. G., Braunstein G. D., Melmed S. Octreotide stimulates insulin-like growth factor binding protein-1 (IGFBP-1) levels in acromegaly. J Clin Endocrinol Metab. 73:1991;441-443.
16. Ezzat S., Ren S. G., Braunstein G. D., Melmed S. Octreotide stimulates insulin-like growth factor-binding protein-1: a potential pituitary-independent mechanism for drug action. J Clin Endocrinol Metab. 75:1992;1459-1463.
17. Ren S. G., Ezzat S., Melmed S., Braunstein G. D. Somatostatin analog induces insulin-like growth factor binding protein-1 (IGFBP-1) expression in human hepatoma cells. Endocrinology. 131:1992;2479-2481.
18. Laursen T., Jørgensen J. O., Ørskov H., Møller J., Harris A. G., Christiansen J. S. Effects of octreotide on insulin-like growth factor I and metabolic indices in growth hormone-treated growth hormone-deficient patients. Acta Endocrinol Copenh. 129:1993;399-408.
19. Nadeau D. A., Sreekumaran Nair K., Rosen C., Copeland K. C. Effect of octreotide on growth hormone induced insulin-like growth factor-I production in humans. Endocrinol Metab. 1:1994;181-185.
20. Blum W. F., Ranke M. B., Kietzmann K., Gauggel E., Zeisel H. J., Bierich J. R. A specific RIA for the growth hormone dependent somatomedin-binding protein: Its use for diagnosis of growth hormone deficiency. J Clin Endocrinol Metab. 70:1990;1292-1298.
21. Fisker S., Frystyk J., Skriver L., Vestbo E., Ho K. K. Y., Ørskov H. A simple, rapid immunometric assay for determination of functional and growth hormone-occupied growth hormone-binding protein in human serum. Eur J Clin Invest. 26:1996;779-785.
22. Frystyk J., Dinesen B., Ørskov H. Non-competitive time-resolved immunofluorometric assays for determination of human insulin-like growth factor I and II. Growth Reg. 5:1995;169-176.
23. Frystyk J., Skjaerbaek C., Dinesen B., Ørskov H. Free insulin-like growth factors (IGF-I and IGF-II) in human serum. FEBS Lett. 348:1994;185-191.
24. Baxter R. C. Circulating levels and molecular distribution of the acid-labile (alpha) subunit of the high molecular weight insulin-like growth factor-binding protein complex. J Clin Endocrinol Metab. 70:1990;1347-1353.
25. Ørskov H., Thomsen H. G., Yde H. Wick Chromatography for rapid and reliable immunoassay of insulin, glucagon and growth hormone. Nature. 219:1968;193-195.
26. Christensen S. E., Weeke J., Ørskov H., Møller N., Flyvbjerg A., Harris A. G., Lund E., Jørgensen J. Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients. Clin Endocrinol Oxf. 27:1987;297-306.
27. Boguszewski C. L., Johannsson G., Bengtsson B. A., Johansson A., Carlsson B., Carlsson L. M. Circulating non-22-kilodalton growth hormone isoforms in acromegalic men before and after transsphenoidal surgery. J Clin Endocrinol Metab. 82:1997;1516-1521.
28. Yumi K., Fagin J. A., Yamashita M., Fishbein M. C., Shah P. K., Kaul S., Niu W., Nilsson J., Cercek B. Direct effects of somatostatin analog octreotide on insulin-like growth factor-I in the arterial wall. Lab Invest. 76:1997;329-338.
29. Grant M. B., Wargovich T. J., Ellis E. A., Caballero S., Mansour M., Pepine C. J. Localization of insulin-like growth factor I and inhibition of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth muscle cells. A potential treatment for restenosis? Circulation. 89:1994;1511-1517.
30. Chan J. M., Stampfer M. J., Giovannucci E., Gann P. H., Ma J., Wilkinson P., Hennekens C. H., Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study [see comments]. Science. 279:1998;563-566.
31. Hankinson S. E., Willett W. C., Colditz G. A., Hunter D. J., Michaud D. S., Deroo B., Rosner B., Speizer F. E., Pollak M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer [In Process Citation]. Lancet. 351:1998;1393-1396.
32. Møller J., Jørgensen J. O., Laursen T., Frystyk J., Naeraa R. W., Ørskov H., Christiansen J. S. Growth hormone dose regimens in adult GH deficiency: effects on biochemical growth markers and metabolic parameters [see comments]. Clin Endocrinol Oxf. 39:1993;403-408.
33. Jørgensen J. O., Vahl N., Hansen T. B., Skjaerbaek C., Fisker S., Ørskov H., Hagen C., Christiansen J. S. Determinants of serum insulin-like growth factor I in growth hormone deficient adults as compared to healthy subjects [In Process Citation]. Clin Endocrinol (Oxf). 48:1998;479-486.
34. Chanson P., Timsit J., Masquet C., Warnet A., Guillausseau P. J., Birman P., Harris A. G., Lubetzki J. Cardiovascular effects of the somatostatin analog octreotide in acromegaly. Ann Intern Med. 113:1990;921-925.
35. Phillips L. S., Pao C. I., Villafuerte B. C. Molecular regulation of insulin-like growth factor-I and its principal binding protein, IGFBP-3. Prog Nucl Acid Res Mol Biol. 60:1998;195-265.
36. Villafuerte B. C., Zhang W. N., Phillips L. S. Insulin and insulin-like growth factor-I regulate hepatic insulin-like growth factor binding protein-3 by different mechanisms. Mol Endocrinol. 10:1996;622-630.
37. Frystyk J., Skjaerbaek C., Alexander N., Emanuelsson H., Suryapranata H., Beyer H., Foegh M., Ørskov H. Lanreotide reduces serum free and total insulin-like growth factor-I after angioplasty. Circulation. 94:1996;2465-2471.
38. Baxter R. C. Insulin-like growth factor binding proteins in the human circulation: a review. Horm Res. 42:1994;140-144.
39. Barreca A., Ponzani P., Arvigo A., Voci A., Giordano G., Minuto F. Functions and regulation of the acid-labile subunit of the 150 K complex. Prog Growth Factor Res. 6:1995;231-239.
40. Barreca A. M., Voci A., Lee P. D., Arvigo M., Ghigliotti V., Fugassa E., Giordano G., Minuto F. Effect of the somatostatin analog, octreotide, and of other hormones on the release of the acid-labile subunit of the 150 kDa complex by rat hepatocyte in primary culture. Eur J Endocrinol. 137:1997;193-199.
41. Barreca A., Cariola G., Ponzani P., Arvigo M., Foppiani L., Giordano G., Minuto F. Effect of octreotide on circulating IGF-I chromatographic profile: evidence for an inhibitory action on the formation of the 150-kDa ternary complex. Clin Endocrinol Oxf. 42:1995;161-167.
42. Skjaerbaek C., Vahl N., Frystyk J., Hansen T. B., Jørgensen J. O., Hagen C., Christiansen J. S., Ørskov H. Serum free insulin-like growth factor-I in growth hormone-deficient adults before and after growth hormone replacement. Eur J Endocrinol. 137:1997;132-137.
43. Wolthers T., Grøfte T., Flyvbjerg A., Frystyk J., Vilstrup H., Ørskov H., Foegh M. Dose-dependent stimulation of insulin-like growth factor-binding protein-1 by lanreotide, a somatostatin analog. J Clin Endocrinol Metab. 78:1994;141-144.
44. Kratzsch J., Keliner K., Zilkens T., Schmidt-Gayk H., Selisko T., Scholz G. H. Growth hormone-binding protein related immunoreactivity is regulated by the degree of insulinopenia in diabetes mellitus. Clin Endocrinol. Oxf. 44:1996;673-678.